BD's CentroVena One™ Receives Vizient Innovative Technology Contract
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: PRnewswire
- Innovative Technology Recognition: BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient, indicating its potential to simplify central line insertion and enhance patient safety, which is expected to drive significant improvements in healthcare delivery.
- Workflow Simplification Advantage: By integrating the guidewire, needle, syringe, and catheter into a single system, the CentroVena One™ reduces procedural steps by 30% and maximum procedure time by 50%, thereby lowering operational complexity and enhancing clinical efficiency.
- Safety-Focused Design Features: The design of CentroVena One™ incorporates safety elements aimed at reducing contamination risks and preventing complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure, further enhancing safety for both patients and clinicians.
- Market Impact: The Vizient contract encompasses over $156 billion in annual purchasing volume, allowing BD to enhance healthcare outcomes, lower costs, and expand access to healthcare through close collaboration with clients, thereby strengthening its competitive position in the medical technology market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 152.900
Low
157.00
Averages
192.64
High
232.00
Current: 152.900
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
BD's CentroVena One™ Receives Vizient Innovative Technology Contract
- Innovative Technology Recognition: BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient, indicating its potential to simplify central line insertion and enhance patient safety, which is expected to drive significant improvements in healthcare delivery.
- Workflow Simplification Advantage: By integrating the guidewire, needle, syringe, and catheter into a single system, the CentroVena One™ reduces procedural steps by 30% and maximum procedure time by 50%, thereby lowering operational complexity and enhancing clinical efficiency.
- Safety-Focused Design Features: The design of CentroVena One™ incorporates safety elements aimed at reducing contamination risks and preventing complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure, further enhancing safety for both patients and clinicians.
- Market Impact: The Vizient contract encompasses over $156 billion in annual purchasing volume, allowing BD to enhance healthcare outcomes, lower costs, and expand access to healthcare through close collaboration with clients, thereby strengthening its competitive position in the medical technology market.
See More
Five Blue Chip Dividend Stocks Worth Holding Forever
- AbbVie's Stability: AbbVie (ABBV), a biopharmaceutical giant, has increased its dividends for 50 consecutive years since becoming independent in 2013, with 12 products exceeding $1 billion in sales by 2025, showcasing its strong market adaptability and long-term growth potential.
- McDonald's Expansion: McDonald's (MCD) operates over 45,000 restaurants globally and is expected to raise its dividend again this year, with analysts projecting high-single-digit earnings growth in the coming years, further solidifying its status as a premium dividend stock.
- Johnson & Johnson's Financial Health: Johnson & Johnson (JNJ) is renowned for its 64 consecutive years of dividend increases and boasts an AAA credit rating, with expected annual earnings growth averaging 8% to 9% over the next few years, demonstrating its robustness and reliability in the healthcare sector.
- Walmart's E-commerce Transformation: Walmart (WMT) has consistently increased its dividend for 53 years, and despite e-commerce competition, its earnings are projected to grow by an average of 9% over the next three to five years, providing strong support for continued dividend growth.
See More
Top Dividend Stocks in Healthcare and Consumer Sectors
- Dividend Growth Leader: AbbVie, a Dividend King since its independence in 2013, has raised its dividend for 50 consecutive years and boasts 12 products exceeding $1 billion in sales by 2025, showcasing its strong competitive position in the biopharmaceutical sector.
- Fast-Food Industry Giant: McDonald's operates over 45,000 locations globally and is expected to continue its dividend growth, with the dividend projected to be only 57% of estimated earnings in 2026, reflecting its robust profitability and ongoing market expansion potential.
- Healthcare Sector Leader: Johnson & Johnson is renowned for its 64 consecutive years of dividend increases, with analysts forecasting annual earnings growth of 8% to 9% over the coming years, demonstrating its resilience in pharmaceuticals and medical devices.
- Retail Giant's Resilience: Walmart has maintained and increased its dividend for 53 years, with expected average earnings growth of 9% over the next three to five years, and its dividend is only 34% of 2026 earnings estimates, indicating its adaptability and market leadership amid e-commerce competition.
See More
Three Dividend Stocks Worth Buying Now
- AbbVie's Growth Potential: Despite AbbVie (ABBV) experiencing a 5% decline in stock price this year, its first-quarter results exceeded expectations, showcasing strong financial performance, with Skyrizi and Rinvoq expected to drive growth into the next decade, boosting investor confidence.
- Walmart's Market Advantage: Walmart (WMT) saw its stock drop after the latest earnings report, yet its Everyday Low Price strategy and extensive retail footprint are expected to help maintain relatively decent sales and earnings during economic downturns, making it a solid long-term hold.
- Becton, Dickinson's Return Potential: Although Becton, Dickinson (BDX) has faced economic challenges and lagged in stock performance, over 90% of its revenue comes from recurring consumables, and its goal of reaching nearly $1 billion in GLP-1-related revenue indicates significant future growth potential.
- Attractiveness of Dividend Kings: AbbVie, Walmart, and Becton, Dickinson are all Dividend Kings, having increased dividends for over 50 consecutive years, appealing to income-seeking investors and providing a sense of security amid market volatility.
See More
Three Dividend Stocks Worth Buying Now
- AbbVie's Long-Term Outlook: Despite a 5% drop in AbbVie’s stock this year, the company exceeded financial expectations, with growth driven by products like Skyrizi and Rinvoq, indicating resilience and innovation in the pharmaceutical sector that should support growth over the next decade.
- Walmart's Market Performance: Walmart's shares fell significantly after its latest earnings report, despite solid results; however, its competitive advantages in retail and a 53-year history of dividend increases make it a strong choice for long-term investors, especially amid economic uncertainty.
- Becton, Dickinson's Growth Potential: Facing economic challenges, Becton, Dickinson generates over 90% of its revenue from recurring consumables, and its goal of reaching $1 billion in GLP-1-related revenue by 2030 highlights its ongoing competitiveness in the medical device market.
- Attractiveness of Dividend Kings: All three companies are Dividend Kings, with AbbVie and Becton, Dickinson raising dividends for 54 and 50 consecutive years respectively, while Walmart has done so for 53 years, demonstrating their commitment to returning value to shareholders, making them suitable for income-focused investors.
See More
West Pharmaceutical Services Stock Stages Strong Comeback
- Significant Stock Rebound: In 2026, West Pharmaceutical Services' stock has risen 32.9% year-to-date, significantly outperforming the industry's 30.3% decline and the S&P 500's 28.2% increase, reflecting a recovery in investor confidence.
- Strong Earnings Drive: The company reported first-quarter revenues of $845 million, a 21% year-over-year increase, with adjusted EPS soaring 47%, prompting management to raise full-year guidance, indicating robust demand in biologics and GLP-1 therapies.
- Biologics Business Growth: The biologics-related business achieved 26% organic growth in the first quarter, benefiting from the widespread adoption of NovaPure packaging solutions, suggesting long-term growth potential in the high-value product sector.
- Regulatory Demand Boost: The implementation of European Annex 1 sterile manufacturing regulations led to a 66% year-over-year increase in related projects, expected to contribute approximately 200 basis points to 2026 revenues, further supporting the company's margin expansion.
See More
BD's CentroVena One™ Receives Vizient Innovative Technology Contract
- Innovative Technology Recognition: BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient, indicating its potential to simplify central line insertion and enhance patient safety, which is expected to drive significant improvements in healthcare delivery.
- Workflow Simplification Advantage: By integrating the guidewire, needle, syringe, and catheter into a single system, the CentroVena One™ reduces procedural steps by 30% and maximum procedure time by 50%, thereby lowering operational complexity and enhancing clinical efficiency.
- Safety-Focused Design Features: The design of CentroVena One™ incorporates safety elements aimed at reducing contamination risks and preventing complications such as air and guidewire embolism, needlestick injuries, and clinician blood exposure, further enhancing safety for both patients and clinicians.
- Market Impact: The Vizient contract encompasses over $156 billion in annual purchasing volume, allowing BD to enhance healthcare outcomes, lower costs, and expand access to healthcare through close collaboration with clients, thereby strengthening its competitive position in the medical technology market.
See More
Five Blue Chip Dividend Stocks Worth Holding Forever
- AbbVie's Stability: AbbVie (ABBV), a biopharmaceutical giant, has increased its dividends for 50 consecutive years since becoming independent in 2013, with 12 products exceeding $1 billion in sales by 2025, showcasing its strong market adaptability and long-term growth potential.
- McDonald's Expansion: McDonald's (MCD) operates over 45,000 restaurants globally and is expected to raise its dividend again this year, with analysts projecting high-single-digit earnings growth in the coming years, further solidifying its status as a premium dividend stock.
- Johnson & Johnson's Financial Health: Johnson & Johnson (JNJ) is renowned for its 64 consecutive years of dividend increases and boasts an AAA credit rating, with expected annual earnings growth averaging 8% to 9% over the next few years, demonstrating its robustness and reliability in the healthcare sector.
- Walmart's E-commerce Transformation: Walmart (WMT) has consistently increased its dividend for 53 years, and despite e-commerce competition, its earnings are projected to grow by an average of 9% over the next three to five years, providing strong support for continued dividend growth.
See More
Top Dividend Stocks in Healthcare and Consumer Sectors
- Dividend Growth Leader: AbbVie, a Dividend King since its independence in 2013, has raised its dividend for 50 consecutive years and boasts 12 products exceeding $1 billion in sales by 2025, showcasing its strong competitive position in the biopharmaceutical sector.
- Fast-Food Industry Giant: McDonald's operates over 45,000 locations globally and is expected to continue its dividend growth, with the dividend projected to be only 57% of estimated earnings in 2026, reflecting its robust profitability and ongoing market expansion potential.
- Healthcare Sector Leader: Johnson & Johnson is renowned for its 64 consecutive years of dividend increases, with analysts forecasting annual earnings growth of 8% to 9% over the coming years, demonstrating its resilience in pharmaceuticals and medical devices.
- Retail Giant's Resilience: Walmart has maintained and increased its dividend for 53 years, with expected average earnings growth of 9% over the next three to five years, and its dividend is only 34% of 2026 earnings estimates, indicating its adaptability and market leadership amid e-commerce competition.
See More
Three Dividend Stocks Worth Buying Now
- AbbVie's Growth Potential: Despite AbbVie (ABBV) experiencing a 5% decline in stock price this year, its first-quarter results exceeded expectations, showcasing strong financial performance, with Skyrizi and Rinvoq expected to drive growth into the next decade, boosting investor confidence.
- Walmart's Market Advantage: Walmart (WMT) saw its stock drop after the latest earnings report, yet its Everyday Low Price strategy and extensive retail footprint are expected to help maintain relatively decent sales and earnings during economic downturns, making it a solid long-term hold.
- Becton, Dickinson's Return Potential: Although Becton, Dickinson (BDX) has faced economic challenges and lagged in stock performance, over 90% of its revenue comes from recurring consumables, and its goal of reaching nearly $1 billion in GLP-1-related revenue indicates significant future growth potential.
- Attractiveness of Dividend Kings: AbbVie, Walmart, and Becton, Dickinson are all Dividend Kings, having increased dividends for over 50 consecutive years, appealing to income-seeking investors and providing a sense of security amid market volatility.
See More
Three Dividend Stocks Worth Buying Now
- AbbVie's Long-Term Outlook: Despite a 5% drop in AbbVie’s stock this year, the company exceeded financial expectations, with growth driven by products like Skyrizi and Rinvoq, indicating resilience and innovation in the pharmaceutical sector that should support growth over the next decade.
- Walmart's Market Performance: Walmart's shares fell significantly after its latest earnings report, despite solid results; however, its competitive advantages in retail and a 53-year history of dividend increases make it a strong choice for long-term investors, especially amid economic uncertainty.
- Becton, Dickinson's Growth Potential: Facing economic challenges, Becton, Dickinson generates over 90% of its revenue from recurring consumables, and its goal of reaching $1 billion in GLP-1-related revenue by 2030 highlights its ongoing competitiveness in the medical device market.
- Attractiveness of Dividend Kings: All three companies are Dividend Kings, with AbbVie and Becton, Dickinson raising dividends for 54 and 50 consecutive years respectively, while Walmart has done so for 53 years, demonstrating their commitment to returning value to shareholders, making them suitable for income-focused investors.
See More
